And demand has virtually never been greater. And so we have large, some of the largest lozenges brands in the world want to give us as much business as we can handle? I believe theoretically, that if we had the capacity right now, we could be doing $100 million of revenues right now, and earning pretax $20 million to $25 million on that business. Now, we’re not doing $100 million revenues right now, we’re upgrading at like $8 million to $10 million, we have equipment coming in short term this month, that’s going to increase our capacity to $15 million in the month of December. So going into the first quarter, our revenues are going to be up dramatically, because we already have demand for that $15 million a business. And we also instituted price increases.
So when our base business, our margins are going to improve significantly and under new business, our margins are even better. So all of a sudden Pharmaloz is going to start generating nice profits that will contribute to the bottom line. And then taking it one step further in the second quarter, we have a new lozenge line and all the ancillary automated equipment that should take us to $30 million or even $35 million of capacity, one rate by the end of the second quarter, which means starting the third quarter, our goal is to be generating at least $30 million in revenues, and generating pretax profits of at least $6 million to $7 million, or even $8 million of pretax profit. Those are serious numbers. So think about the swing in our earnings and in our cash flow and in our EBITDA just in the next quarter to just from formalize and understand when I talked about $30 million to $35 million of capacity.
We already have the demand for that as well right now. And that’s without the too big loss and spreads that want to give us another business. So it gives you an idea of the dynamics of formalizing what’s going on there. And I have been told, don’t quote me on this, but the private equity will pay 10 to 15 times pretax. So you can start to see what the numbers could look like and feel like very quickly in the coming quarters. And again, if you read the press releases, and we’re doing this, we already have the plans for it. We have two more lozenge lines already ordered, that are coming in late next year, that are going to take us up to and depending on which press release in which presentation. And you know the numbers, it’s not an exact science.
We’re talking $60 million to $80 million revenues, but understand that’s based on a three and a half day work week. Now you have to have downtime for maintenance and things like that. But you don’t need three and a half days of downtime. And it’s a matter of making sure we have enough employees and it’s one of the reasons why we’re bringing a lot more automated equipment. But in addition to that, we have to find the supply of employees to build it out. So we don’t know sitting here today what the numbers are going to be. But there’s a potential that potential that our capacity could be $80 million to $200 million by the end of next year. And could you imagine if we were generating $20 million $25 million of pretax and multiply 10 to 15 times that, I mean, we’re talking about a facility that could be worth $300 million.
Now, I don’t want to get carried away. I’m not suggesting it’s going to be worth that I’m not saying that’s even our objective. But the point is with that kind of potential, and a market cap of our company that trades around $70 million to $80 million, we have a manufacturing facility that could be worth significantly more than the whole market cap of our company next year by itself. And again, my background is in investment banking, on Wall Street. And so I’d be silly not to pursue all avenues in that regard. So I can talk more in the Q&A, but it just gives you a little bit of background and I’m not suggesting we’re actually doing a race on one of our subsidiaries or that we’re doing anything at present. I’m just explaining that we do have options available to us so that our shareholders are rest assured that I’m not going to do what so many other microcap development stage companies do and that’s blindside you with a an equity raise.
It’s simply not happening at ProPhase Labs, the parent company. All right. And I can guarantee at some point in the future something will change but I can tell you for the foreseeable future don’t have the slightest interest in such an activity. Okay? Nebula Genomics. Now, Pharmaloz to me, I don’t want to sell to anybody to me it’s sort of a boring ho-hum business. One of our senior employees here who’s working on this, says no, Ted, this is very exciting. And yeah, it is very exciting. From a numbers point of view, it’s not exciting from the point of view, it’s not like biotech. It’s not like development, stage cancer testing, cancer therapeutics and things of that nature. But Pharmaloz, obviously, it’s exciting from a numbers point of view.
